top of page
  • Completed

NCT04445701: Phase 1/2: Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dex RRMM

Updated: Feb 21


  • NCT04445701: Phase 1/2: Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma


a0176

Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma


Open-label, dose escalation study to evaluate the safety, tolerability, pharmacokinetics (PK)/pharmacodynamics and initial efficacy of AO-176 as monotherapy and in combination with dexamethasone and bortezomib in adults with relapsed/refractory multiple myeloma (MM).


Sponsor

Arch Oncology

 

ClinicalTrials.gov Identifier: NCT04445701


Official Title: A Phase 1/2, Dose Escalation Safety and Tolerability Study of AO-176 as Monotherapy and in Combination With Bortezomib and Dexamethasone in Adults With Relapsed or Refractory Multiple Myeloma


First Posted : June 24, 2020


Click here to see details on ClinicalTrials.gov

 

Drug: AO-176 Drug: AO-176 + Dex

Drug: AO-176 + Dex + Bort

Anti-CD47 Monoclonal Antibody AO-176 (Code C159600)

Anti-CD47 Monoclonal Antibody AO-176

AO 176

AO-176

AO176

 

Locations

United States, Arizona

United States, Florida

United States, Georgia

United States, Massachusetts

United States, Minnesota

United States, Washington

United States, Wisconsin

Commentaires


Les commentaires ont été désactivés.
Posts Archive
bottom of page